TME PHARM.CONF.IPO EO 1- (0N6A) — Net Asset Quality Index
TME PHARM.CONF.IPO EO 1- (0N6A) has a Net Asset Quality Index of -73.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €2.14 Million minus total liabilities of €3.72 Million yields net assets of €-1.58 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read 0N6A total debt and obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
TME PHARM.CONF.IPO EO 1- Net Asset Quality Index Over Time (2021–2025)
This chart shows how TME PHARM.CONF.IPO EO 1-'s Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at -73.8%, representing net assets of €-1.58 Million against total assets of €2.14 Million EUR. For live market cap and overall valuation, see TME PHARM.CONF.IPO EO 1- (0N6A) total market value.
Annual Net Asset Quality Index for TME PHARM.CONF.IPO EO 1- (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for TME PHARM.CONF.IPO EO 1- from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See TME PHARM.CONF.IPO EO 1- book value and equity for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -73.8% | €-1.58 Million | €2.14 Million | €3.72 Million | ▼ -121.2 pp |
| 2024 | 47.4% | €1.61 Million | €3.41 Million | €1.79 Million | ▲ +59.2 pp |
| 2023 | -11.8% | €-294.00K | €2.49 Million | €2.79 Million | ▲ +12.5 pp |
| 2022 | -24.3% | €-1.27 Million | €5.24 Million | €6.51 Million | ▼ -70.4 pp |
| 2021 | 46.1% | €4.50 Million | €9.77 Million | €5.27 Million | — |